author-photo

John D. Powderly

Medarex

112

Papers

20857

Citations

Citation Trend

Filter By

Papers (79) Sort By

Journal Conference Others

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (9)
596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)